The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
AIMS/HYPOTHESIS: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis to examine whether sex modifies these effects.
METHODS: The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years). The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained ≥40% drop in eGFR to <60 ml min-1 [1.73 m]-2, new end-stage renal disease or renal death. Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome.
RESULTS: At baseline, women (n = 6422, 37.4%) had higher HbA1c, longer type 2 diabetes duration, and were on fewer glucose-lowering medications. There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; pinteraction = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; pinteraction = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; pinteraction = 0.64). The overall safety profile of dapagliflozin was similar for women and men.
CONCLUSIONS/INTERPRETATION: Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men.
FUNDING: AstraZeneca.
TRIAL REGISTRATION: clinicaltrials.gov NCT01730534.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
---|---|
Enthalten in: |
Diabetologia - 64(2021), 6 vom: 10. Juni, Seite 1226-1234 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
O'Donoghue, Michelle L [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 22.02.2022 Date Revised 22.02.2022 published: Print-Electronic ClinicalTrials.gov: NCT01730534 Citation Status MEDLINE |
---|
doi: |
10.1007/s00125-021-05399-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321702220 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321702220 | ||
003 | DE-627 | ||
005 | 20231225180439.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00125-021-05399-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1072.xml |
035 | |a (DE-627)NLM321702220 | ||
035 | |a (NLM)33611623 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a O'Donoghue, Michelle L |e verfasserin |4 aut | |
245 | 1 | 4 | |a The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2022 | ||
500 | |a Date Revised 22.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT01730534 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a AIMS/HYPOTHESIS: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis to examine whether sex modifies these effects | ||
520 | |a METHODS: The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years). The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained ≥40% drop in eGFR to <60 ml min-1 [1.73 m]-2, new end-stage renal disease or renal death. Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome | ||
520 | |a RESULTS: At baseline, women (n = 6422, 37.4%) had higher HbA1c, longer type 2 diabetes duration, and were on fewer glucose-lowering medications. There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; pinteraction = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; pinteraction = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; pinteraction = 0.64). The overall safety profile of dapagliflozin was similar for women and men | ||
520 | |a CONCLUSIONS/INTERPRETATION: Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men | ||
520 | |a FUNDING: AstraZeneca | ||
520 | |a TRIAL REGISTRATION: clinicaltrials.gov NCT01730534 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Cardiovascular outcomes | |
650 | 4 | |a Clinical trials | |
650 | 4 | |a SGLT2 inhibitors | |
650 | 4 | |a Women | |
650 | 7 | |a Benzhydryl Compounds |2 NLM | |
650 | 7 | |a Glucosides |2 NLM | |
650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
650 | 7 | |a dapagliflozin |2 NLM | |
650 | 7 | |a 1ULL0QJ8UC |2 NLM | |
700 | 1 | |a Kato, Eri T |e verfasserin |4 aut | |
700 | 1 | |a Mosenzon, Ofri |e verfasserin |4 aut | |
700 | 1 | |a Murphy, Sabina A |e verfasserin |4 aut | |
700 | 1 | |a Cahn, Avivit |e verfasserin |4 aut | |
700 | 1 | |a Herrera, Marisol |e verfasserin |4 aut | |
700 | 1 | |a Tankova, Tsvetalina |e verfasserin |4 aut | |
700 | 1 | |a Šmahelová, Alena |e verfasserin |4 aut | |
700 | 1 | |a Merlini, Piera |e verfasserin |4 aut | |
700 | 1 | |a Gause-Nilsson, Ingrid |e verfasserin |4 aut | |
700 | 1 | |a Langkilde, Anna Maria |e verfasserin |4 aut | |
700 | 1 | |a McGuire, Darren K |e verfasserin |4 aut | |
700 | 1 | |a Wilding, John P H |e verfasserin |4 aut | |
700 | 1 | |a Leiter, Larry A |e verfasserin |4 aut | |
700 | 1 | |a Bhatt, Deepak L |e verfasserin |4 aut | |
700 | 1 | |a Raz, Itamar |e verfasserin |4 aut | |
700 | 1 | |a Sabatine, Marc S |e verfasserin |4 aut | |
700 | 1 | |a Wiviott, Stephen D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetologia |d 1966 |g 64(2021), 6 vom: 10. Juni, Seite 1226-1234 |w (DE-627)NLM000017035 |x 1432-0428 |7 nnns |
773 | 1 | 8 | |g volume:64 |g year:2021 |g number:6 |g day:10 |g month:06 |g pages:1226-1234 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00125-021-05399-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 64 |j 2021 |e 6 |b 10 |c 06 |h 1226-1234 |